2024-03-28T08:02:37Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1739472022-11-22T13:51:41Zcom_10261_108com_10261_8col_10261_361
2019-01-11T09:58:34Z
urn:hdl:10261/173947
Complement component 3: a new paradigm in tuberculosis vaccine
Fuente, José de la
Gortázar, Christian
Juste, Ramón A.
Ministerio de Economía y Competitividad (España)
European Commission
Mycobacteria
Vaccine
Immunology
Complement
Tuberculosis
Vaccines are critical for the control of tuberculosis (TB) affecting humans and animals worldwide. First-generation vaccines protect from active TB but new vaccines are required to protect against pulmonary disease and infection. Recent advances in post-genomics technologies have allowed the characterization of host-pathogen interactions to discover new protective antigens and mechanisms to develop more effective vaccines against TB. Studies in the wild boar model resulted in the identification of complement component 3 (C3) as a natural correlate of protection against TB. Oral immunization with heat-inactivated mycobacteria protected wild boar against TB and showed that C3 plays a central role in protection. These results point at C3 as a target to develop novel vaccine formulations for more effective protection against TB in humans and animals.
2019-01-11T09:58:34Z
2019-01-11T09:58:34Z
2016
2019-01-11T09:58:34Z
artículo
Expert Review of Vaccines 15(3): 275-277 (2016)
http://hdl.handle.net/10261/173947
10.1586/14760584.2016.1125294
http://dx.doi.org/10.13039/501100003329
http://dx.doi.org/10.13039/501100000780
26605515
eng
Sí
info:eu-repo/grantAgreement/EC/FP7/613779
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/AGL2014-56305-C3-1-R
closedAccess
Taylor & Francis